Coya Therapeutics reports FY2023 net loss of $8.0M; cash $32.6M plus $7.5M upfront from Dr. Reddy's

Coya Therapeutics, Inc.

Net loss improved to $8.0M in FY2023 from $12.2M in FY2022; R&D spend $5.5M, G&A $7.8M.
Cash and equivalents $32.6M at Dec 31, 2023; plus $7.5M upfront from Dr. Reddy's received Jan 2024.
Closed Jan 2023 IPO net $14.1M and Dec 2023 private placement net $24.0M.
Dr. Reddy's collaboration for COYA 302 in ALS: up to $733M milestones plus low-to-mid teens royalties.
IND for COYA 302 in ALS expected 2Q24; Ph.2 topline data targeted for 2025.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Coya Therapeutics, Inc. reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 19, 2024, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2023.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-033159

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.